DPT Laboratories, a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms, and Confab, a DPT company specializing in complex solids, semi-solids and liquids, have completed a combined $10 million capital investment demonstrating their commitment to continuous improvement.
San Antonio-based DPT has invested in a new compounding suite and significant upgrades to production filling lines that will increase capacity, throughput and precision. Additional upgrades include a remodeled front office area and enhanced security to further restrict access to the manufacturing floor and further enhance GMP compliance.
Confab, based in Montreal, made a significant investment to increase R&D capabilities with a new state-of-the-art laboratory, new equipment and expansion of its R&D team. Confab can now offer customers pharmaceutical development capabilities ranging from formulation development and analytical method development to technology transfers at commercial scale.
“The investments in capital demonstrate our continuing commitment to provide high-quality development and manufacturing solutions to our partners,” said Paul Josephs, senior vice president of sales, marketing and corporate development. “We are excited about the strong demand for our services and look forward to discussing our enhanced capabilities with our customers during DCAT week.”